SAFETY-VAC: Phenotype proposal and rates of immunocompromised populations in real-world data sources.

First published: 24/02/2025

Last updated: 24/02/2025



Denmark



Administrative details

PURI
https://redirect.ema.europa.eu/resource/1000000288
EU PAS number
EUPAS1000000288
Study ID
100000288
DARWIN EU® study
No
Study countries

Finland		
France		
Italy		
Norway		
Spain		
United Kingdom		

Study description


This SAFETY-VAC project aims to provide a consolidated approach to identify and characterise immunocompromised populations in real-world data sources and to produce incidence and prevalence rates for these populations using electronic healthcare records databases.

Study status

Planned

Research institutions and networks

Institutions



Aarhus University & Aarhus University Hospital DEPARTMENT OF CLINICAL EPIDEMIOLOGY Denmark First published: 20/07/2021 Last updated: 02/04/2024 Institution Educational Institution ENCePP partner




Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

Spain

First published: 05/10/2012

Last updated: 23/02/2024



The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)

Spain

First published: 01/02/2024

Last updated: 05/11/2024

Institution

Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Medical Devices, AEMPS)

Spain

First published: 01/02/2024

Last updated: 04/09/2024

Institution

EU Institution/Body/Agency

Not-for-profit

Regulatory Authority

ENCePP partner

University of Oslo

First published: 01/02/2024

Last updated: 01/02/2024
Institution
Teamit Institute
Spain Spain
First published: 12/03/2024
Last updated: 12/03/2024
Institution Other ENCePP partner
Utretch University (UU), University of Eastern
Finland (UEF)
Networks
\\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
Vaccine monitoring Collaboration for Europe
(VAC4EU)
Belgium
Denmark
Finland — –
France
Germany
☐ Italy ☐ Netherlands

Norway
Spain
United Kingdom
First published: 22/09/2020
Last updated: 22/09/2020
Network ENCePP partner

EU Pharmacoepidemiology and Pharmacovigilance (PE&PV) Research Network

Netherlands

First published: 01/02/2024

Last updated: 26/11/2024

Network

Contact details

Study institution contact

Fabio Riefolo

Study contact

friefolo@teamitresearch.com

Primary lead investigator

Carlos Durán Salinas

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 15/01/2024 Actual: 06/02/2024

Study start date

Planned: 15/05/2024

Date of final study report

Planned: 16/09/2024

Sources of funding

EMA

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Method development or testing

Data collection methods:

Secondary use of data

Study design:

- Scoping review aimed at describing and identifying immunocompromised populations in epidemiological studies using EHRs.
- Retrospective cohort study from January 1, 2017, to the last available data aimed at identifying and characterizing these populations using RWD.

Main study objective:

- To describe what operational definitions are used to identify immunocompromised populations when conducting epidemiological research in EHR databases and propose a phenotype to identify immunocompromised individuals in database studies correctly.
- To estimate the incidence and one-year prevalence rates of immunocompromised status based on the agreed phenotype and different durations of episodes.
- To assess the contribution of different provenances of data and durations to the prevalence of the immunocompromised status.

Study Design

Non-interventional study design

Cohort

Population studied

Short description of the study population

Electronic health records of people from 10 data sources in 7 countries in Europe from January 1st, 2017, until the last data availability were selected. Persons were included in the study population when they had:

- Information on age and gender available,
- At least one day of follow in the study period (1/1/2017- latest availability). Follow-up started at the latest date of any of the following dates: day that one year of lookback is available during the study period, or at 1/1/2017 when the person is born in the data base.

Follow-up finished at the earliest of the following dates: death, disenrollment, end of study period, or recommended end date.

Age groups

Paediatric Population (< 18 years)

Adult and elderly population (≥18 years)

Study design details

Setting

The study will use data from 10 secondary electronic health record databases that are population-based in 7 countries in Europe (UK, Spain, Denmark, Finland, Norway, Italy and France).

The study will be conducted during the period from January 1st, 2017, to the last data availability, specific for each data source.

The source population comprises all persons in the data sources who can be potentially included in the study.

Documents

Study report

SAFETY-VAC Immunocompromised population D4 Report.pdf(1009.31 KB)

Data management

Data sources

Data source(s)

Pedianet network

Norwegian Health Registers

The Valencia Health System Integrated Database

EpiChron Cohort

Danish Health Data Registries

Système National des Données de Santé (French national health system main database)

BIFAP - Base de Datos para la Investigación Farmacoepidemiológica en el Ámbito Público (Pharmacoepidemiological Research Database for Public Health Systems)

Clinical Practice Research Datalink (CPRD) GOLD

The Information System for Research in Primary Care (SIDIAP)

Data source(s), other

Finnish national data registers

Use of a Common Data Model (CDM)

CDM mapping

Yes

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

Yes